The short answer: mass-market compounded semaglutide and tirzepatide are no longer legal, and they were never FDA-approved or tested for safety. The legal window existed only because the brand drugs were in shortage; the FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved on February 21, 2025, and the compounding wind-down deadlines passed by May 22, 2025. On safety, the FDA had logged 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026, including hospitalizations from dosing errors.

What is a compounded GLP-1 drug?

Compounding is when a licensed pharmacy or an outsourcing facility mixes a drug itself rather than dispensing a manufactured product. It exists for real medical needs: a patient who is allergic to a dye in the commercial tablet, or a child who needs a liquid version of a drug sold only as a pill.

Compounded GLP-1s were something different in scale. During the 2022–2024 supply crunch, telehealth companies and med spas sold compounded semaglutide and tirzepatide, usually as multi-dose vials with syringes, at a fraction of the brand price. The products copied the active ingredient of Ozempic, Wegovy, Mounjaro, and Zepbound, but no compounded drug is FDA-approved. The agency does not review compounded drugs for safety, effectiveness, or quality before they are sold (FDA).

Federal law normally bars compounders from making what the FDA calls “essentially a copy” of a commercially available drug: same active ingredient, same or similar strength, when the commercial product would work for the patient. The exception is a drug on the FDA's official shortage list. While a drug is in shortage, copies are permitted, and semaglutide injection sat on that list from 2022 (FDA compounding policy updates).

That exception is the entire legal foundation the compounded GLP-1 industry was built on. It was always temporary by design: the moment the manufacturer could meet national demand, the foundation was scheduled to disappear.

For routine copies, no. The timeline, all from the FDA's own updates:

  • December 19, 2024: the FDA declared the tirzepatide shortage resolved.
  • February 21, 2025: the FDA declared the semaglutide shortage resolved.
  • March 19, 2025: end of the grace period for 503B outsourcing facilities compounding tirzepatide.
  • April 22, 2025: end of the grace period for 503A state-licensed pharmacies compounding semaglutide.
  • May 22, 2025: end of the grace period for 503B outsourcing facilities compounding semaglutide.

A compounding trade group, the Outsourcing Facilities Association, sued to overturn both shortage determinations. Federal district courts denied the preliminary injunctions, on March 5, 2025 for tirzepatide and April 24, 2025 for semaglutide, and the deadlines held (FDA).

Narrow exceptions survive. A 503A pharmacy can still compound for an individual patient with a documented clinical need the approved product cannot meet, such as an allergy to an inactive ingredient. What is not permitted is the pre-2025 business model: producing copies at volume because they are cheaper. And in April 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulk substances list, which would permanently close the remaining large-scale pathway (Pharmacy Times).

How safe are compounded GLP-1 drugs?

The honest answer is that nobody fully knows, which is itself the problem. Approved drugs carry trial data on thousands of patients and manufacturing oversight of every batch. Compounded drugs carry neither. What the FDA does have is adverse event reports, and the count keeps climbing: as of May 31, 2026, 990 reports for compounded semaglutide and more than 730 for compounded tirzepatide. The agency notes that state-licensed pharmacies are not required to report adverse events at all, so the true numbers are likely higher (FDA).

The most consistent documented harm is dosing error. Brand GLP-1s come in prefilled pens with fixed doses. Compounded versions usually come as a vial and syringe, in concentrations that vary by compounder. The FDA's alert on the subject describes patients told to draw 5 units who drew 50, a tenfold overdose, and providers who miscalculated conversions between milligrams, milliliters, and syringe units. Some of these overdoses required hospitalization (FDA, dosing error alert).

Beyond dosing, the FDA has documented compounded products with fraudulent labels naming pharmacies that never made them, and outright counterfeit Ozempic circulating in the U.S. supply, which can contain the wrong ingredient or none at all. Our sibling site covers the brand drug itself at ozempic.md.

What about salt forms and “personalized” doses?

Two marketing claims deserve specific caution.

Salt forms. Some compounders have used semaglutide sodium or semaglutide acetate, which are different active ingredients from the base semaglutide in the approved drugs. The FDA states it has no information showing these salts behave the same chemically or pharmacologically, and that it is aware of no lawful basis for using them in compounding at all, shortage or no shortage (FDA).

“Personalized” dosing. Some sellers pitch custom doses or added vitamins as the clinical difference that keeps their product legal. The FDA has received adverse event reports tied to compounded GLP-1s prescribed at doses beyond the approved labeling, including larger single doses and faster escalation schedules. A tweak that exists to dodge the copy rule is not a documented clinical need, and higher-than-labeled doses have no trial evidence behind them.

Most people did not choose compounded drugs out of preference. They chose them because brand GLP-1s list at about $1,349 per month and insurance often refuses to cover weight management. That math has changed since the compounding era ended, because both manufacturers now sell directly to self-pay patients:

  • Wegovy: Novo Nordisk's NovoCare Pharmacy lists self-pay pens at $349 per month for standard doses (0.25–2.4 mg), with introductory offers as low as $199 for new patients, against a list price of $1,349.02 (NovoCare).
  • Zepbound: Eli Lilly's self-pay programs list the 2.5 mg starting dose at $299 per month, 5 mg at $399, and higher doses at $449 per month under its refill purchase offer (Lilly).

Prices and eligibility terms change often, so verify on the manufacturer sites. For the full picture, including insurance strategies and savings cards, see our guides to GLP-1 cost and insurance and whether insurance covers GLP-1s. If price is pushing you toward a different drug in the class entirely, our head-to-head comparison covers the trade-offs.

The bottom line

Compounded GLP-1s were a shortage-era workaround, and the shortage is over. The legal basis for mass-produced copies ended in the spring of 2025, courts declined to revive it, and the FDA is moving to close the last pathway permanently. The safety record that accumulated in the meantime, nearly 1,000 adverse event reports for compounded semaglutide alone, dosing errors, salt forms, and counterfeits, is the argument against seeking the products that remain online. If you are still using a compounded GLP-1, talk to your prescriber about moving to an approved product; the self-pay prices are no longer $1,000 a month.

Last updated: August 2026. This article is for informational purposes only and does not constitute medical advice. Do not start, stop, or change a prescription medication without talking to your prescriber.